OPT Share Price Performance
AU$0.60
0.18 (44.58%)
86.6% undervalued intrinsic discount
AU$4.48
Fair Value
Price AU$0.60
StockMan AU$4.48
Fair ValueAU$0.10
Share PriceAU$0.60
500.0% overvalued intrinsic discount
OPT Community Narratives
ST
Fair Value AU$0.10 500.0% overvalued intrinsic discount
OPTHEA - Write-off
17users have liked this narrative
2users have commented on this narrative
26users have followed this narrative
Recent OPT News & Updates
No updates
Opthea Limited Key Details
Last Reported Earnings
Dec 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.20
- Gross Margin
- 100.00%
- Net Profit Margin
- -119,924.98%
- Debt/Equity Ratio
- -132.0%
Opthea Limited Competitors
About OPT
- Founded
- 1984
- Employees
- 33
- CEO
- WebsiteView website
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
Australian Market Performance
- 7 Days: 1.2%
- 3 Months: 7.7%
- 1 Year: 15.0%
- Year to Date: 7.3%
Over the last 7 days, the market has risen 1.1%, driven by gains of 1.1% in the Financials sector. In the last year, the market has climbed 15%. Earnings are forecast to grow by 11% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading